August 16, 2017
CÚRAM Continues To Strengthen MedTech Ecosystem With New US industry Partnership
CÚRAM, the Science Foundation Ireland Centre for Research in Medical Devices, based at NUI Galway, has recently signed a collaborative research agreement with Factor Bioscience, a US based biotechnology SME that is pioneering nucleic-acid and cell-based technologies to advance the study and treatment of disease, including respiratory disease. This is the US company’s first collaboration in Ireland.
The project goal is to determine the translational potential of a synthetic product from Factor Bioscience for use in Acute Respiratory Distress Syndrome (ARDS). ARDS often affects the elderly and occurs when fluid builds up in the air sacs in the lungs and prevents them from filling with enough air. This means less oxygen is available to reach the bloodstream which deprives the organs of the oxygen they need to function properly. ARDS typically occurs in people who are already critically ill or who have significant injuries, and many people who develop ARDS don’t survive. Those who do can experience lasting damage to their lungs.
“Factor engages in research collaborations to advance and deploy our technologies as quickly and broadly as possible”, says Matt Angel, Co-founder of Factor Bioscience. “We are an early-stage biotechnology company based in the Boston area with an Irish subsidiary, and we are looking to grow our operations in Ireland. By partnering with CÚRAM on this project we can access leading experts and resources in the medical device field, which will hopefully allow us to progress much faster in finding a better solution for patients suffering from ARDS.”
February 28, 2023
Factor Bioscience Announces Publication of Preclinical Results of Aerosolized mRNA For the Treatment of Pneumonia
February 22, 2023
Eterna Therapeutics Enters Into Option and License Agreement With Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
January 4, 2023
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
May 16, 2022
Factor Bioscience to Deliver Four Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting